(+64) 09 302 0221
70 Symonds Street, Grafton, Auckland, Auckland 1010
Info@apercure.comg.watts@apercure.com
20 October 2025
Apercure Initiates In-Hospital Clinical Trial of the LIMPIT®.
Apercure Surgical Limited is pleased to announce the commencement of its first in-hospital clinical trial for the LIMPIT® device — a next-generation securement solution for percutaneous drainage catheters and surgical drains.
The study, conducted at a leading New Zealand public hospital, marks a major step forward in validating LIMPIT’s performance in a real-world clinical setting. The trial is designed to evaluate the device’s safety, usability, and clinical efficacy across a representative cohort of surgical patients and procedures.
Key opinion leaders, including senior interventional radiologists and surgical consultants, are overseeing the trial, supported by a dedicated team of experienced nursing staff. Early feedback from both clinicians and patients has been overwhelmingly positive, with nurses highlighting the device’s intuitive application and patients reporting high levels of comfort and minimal interference with movement or dressing changes.
“This trial represents a major milestone in the evolution of surgical drain management,” said Gregory Watts, CEO of Apercure. “We’ve been encouraged by the clinical team’s response to the device, and we’re grateful for their support in helping us evaluate LIMPIT in a high-acuity environment.”
Initial impressions indicate the device offers significant advantages over conventional suture and other adhesive-based securement methods, particularly in enhancing patient comfort, improving dressing access, and reducing the risk of catheter dislodgement or skin complications. Data collected during the study will support regulatory submission and inform the next phase of clinical and commercial deployment.
“We’d like to thank the surgeons, nursing teams, and patients who have partnered with us in this trial,” added Watts. “Their contributions are crucial in demonstrating LIMPIT’s potential to improve outcomes and ease of care in the surgical setting.”
Apercure remains focused on progressing the LIMPIT device toward market introduction in Q1 2026 and continues to work closely with regulatory, clinical, and manufacturing partners as it advances its innovation pipeline.
15 February 2025
Apercure achieves major milestone with successful completion of first clinical trial for LIMPIT® surgical device
Apercure Surgical Limited is pleased to announce the successful completion of its first clinical trial for the LIMPIT® device — a next-generation solution for securement of surgical drains. The trial evaluated the device's safety, usability, and effectiveness in a real-world clinical setting. Results confirmed that LIMPIT delivers measurable improvements in surgical precision, reduces drain-related complications, and enhances post-operative recovery when compared to traditional methods.
“The results validate years of innovation and development,” said Gregory Watts, CEO of Apercure. “This is a major step toward transforming how surgical drains are secured and managed.”
The trial involved rigorous assessment across a broad cohort of participants. Results demonstrated strong performance in terms of device reliability, patient comfort, and clinician ease-of-use. The comprehensive data collected supports the device’s safety and effectiveness, and will inform the next steps toward regulatory submission and market introduction.
Having already passed rigorous preclinical testing, the LIMPIT device is now a step closer to market introduction. Apercure is actively preparing for expanded clinical use and continued engagement with regulatory and clinical partners.
“We extend our sincere thanks to the dedicated medical team, ethics committee, and volunteers who participated in this trial,” added Watts. “Their involvement has been critical in demonstrating that LIMPIT can play a meaningful role in improving surgical care.”
The completion of this clinical trial is a significant validation of Apercure’s approach to innovation in the medical device space. The company remains focused on advancing its technology pipeline, supporting healthcare professionals, and delivering better outcomes for patients worldwide.
25th November 2024
Apercure Announces Commencement of LIMPIT Clinical Trials for Revolutionary Surgical Device.
Apercure Surgical Limited is pleased to announce the official commencement of its highly anticipated LIMPIT Clinical Trials, a pivotal step in the development of its innovative medical device aimed at improving patient outcomes in minimally invasive procedures. The trial, which marks a significant milestone for Apercure, will evaluate the safety, efficacy, and usability of the LIMPIT device in a clinical setting.
The LIMPIT Clinical Trial involves collaboration with leading surgeons and healthcare facilities to rigorously test the device’s performance in real-world surgical scenarios. The trial is designed to provide comprehensive data on the device’s ability to enhance precision, reduce complications, and support faster patient recovery times compared to traditional methods.
“This is a major step forward in our journey to bring the LIMPIT device to market,” said Gregory Watts, CEO of Apercure. “We’ve spent years refining this technology to address critical challenges in minimally invasive surgery, and the commencement of this trial represents our commitment to delivering safe, effective, and innovative solutions to the healthcare community.”
The LIMPIT device has undergone extensive preclinical testing, demonstrating promising results in terms of accuracy, reliability, and patient safety. The clinical trial will involve a multi-phase approach, starting with initial patient enrollment and device application, followed by thorough post-operative monitoring to evaluate outcomes. The data collected during the trial will play a key role in securing regulatory approvals and preparing for commercial distribution.
Apercure is committed to maintaining the highest standards of ethics and patient safety throughout the clinical trial process. The trial protocol has been approved by relevant regulatory authorities and ethics committees, ensuring full compliance with global clinical standards.
“We are excited to work with top medical professionals as we evaluate the potential of the LIMPIT device to transform minimally invasive procedures,” added Watts. “This clinical trial brings us closer to our goal of improving surgical precision and delivering better outcomes for patients worldwide.”
The LIMPIT Clinical Trial is a testament to Apercure’s dedication to advancing surgical technology and fostering innovation in the medical device sector. As the trial progresses, the company remains focused on its mission to develop products that address the unmet needs of healthcare providers and patients.
Further updates on the LIMPIT Clinical Trial, including preliminary results and milestones, will be shared as they become available. Apercure extends its gratitude to the medical teams and participants who are helping to make this groundbreaking trial possible.
With the launch of the LIMPIT Clinical Trial, Apercure continues to lead the way in revolutionizing surgical care through innovation, research, and a steadfast commitment to improving patient outcomes.
16th June 2024
Apercure Surgical Limited Appoints Gregory Watts as New CEO
Apercure Surgical Limited, a leader in innovative surgical device solutions, is excited to announce the appointment of Gregory Watts as its new Chief Executive Officer. With over two decades of experience in the heath & wellbeing sectors, Gregory brings a wealth of knowledge and leadership expertise that will guide Apercure through its next phase of growth and innovation.
Prior to joining Apercure, Gregory served as CEO of several heath & wellbeing companies, where he led transformative initiatives, drove operational efficiency, and spearheaded global expansion strategies. His deep understanding of the regulatory landscape, product development, and commercialization processes will be invaluable in advancing Apercure’s mission to deliver high-quality surgical devices that meet the evolving needs of healthcare professionals and patients worldwide.
“We are thrilled to welcome Gregory to Apercure,” said the Board of Directors. “His proven track record of leading successful companies, his visionary leadership, and his commitment to innovation in the medical device space make him the ideal fit to drive Apercure forward. We are confident that under his leadership, Apercure will continue to strengthen its position in the market and expand its portfolio of cutting-edge surgical solutions.”
Gregory’s appointment comes at a pivotal time for Apercure, as the company is advancing several new product lines and expanding its presence in international markets. His focus will be on enhancing Apercure’s research and development capabilities, driving operational excellence, and reinforcing the company’s commitment to patient safety and regulatory compliance.
“I am honored to join Apercure and work alongside such a talented team,” said Watts. “The company’s dedication to innovation and improving patient outcomes aligns perfectly with my passion for advancing medical technologies. I look forward to collaborating with the team to continue delivering high-quality surgical devices that make a meaningful impact on the healthcare industry.”
As CEO, Gregory will lead Apercure’s ongoing efforts to push the boundaries of medical device innovation while ensuring that its products meet the highest standards of safety and efficacy. He will also play a key role in expanding strategic partnerships and advancing Apercure’s vision of becoming a global leader in surgical solutions.
Apercure Surgical Limited looks forward to a bright future under Gregory’s leadership as the company continues to deliver exceptional products and services to healthcare providers worldwide.
4th April 2023
Apercure Surgical Limited Secures Seed Funding from WNT to Accelerate Innovation in Surgical Devices
Apercure Surgical Limited, a cutting-edge medical device company focused on revolutionizing surgical solutions, is pleased to announce the successful completion of its seed funding round, securing a significant investment from WNT Ventures. The funding will enable Apercure to accelerate the development of its innovative surgical devices and expand its research and development capabilities.
WNT Ventures, a renowned venture capital firm specializing in early-stage investments in high-growth sectors, has shown strong confidence in Apercure's potential. The partnership marks a pivotal milestone in Apercure's growth trajectory, providing the necessary resources to bring its next-generation surgical technologies to market faster.
"We are thrilled to partner with WNT Ventures as we continue to push the boundaries of surgical innovation," said Apercure’s CEO Gregory Watts. "This investment will play a key role in advancing our mission to develop safe, effective, and user-friendly surgical devices that address the evolving needs of healthcare providers and patients. WNT's support will enable us to accelerate product development, expand our clinical trials, and further strengthen our regulatory compliance efforts."
The seed funding will be used to enhance Apercure's product development pipeline, focusing on refining existing prototypes and expanding its portfolio of surgical devices. Additionally, Apercure plans to invest in cutting-edge research, clinical trials, and regulatory processes to ensure its products meet the highest standards of safety and efficacy. The investment will also support the company's efforts to scale operations and expand its market presence both locally and internationally.
Apercure’s innovative approach to surgical devices has already garnered significant interest from healthcare providers and industry leaders, and the company is well-positioned to make a lasting impact in the medical device space. The company’s commitment to rigorous testing, compliance with global regulations, and a strong focus on patient safety ensures that Apercure’s devices meet the highest standards of quality.
"We are excited to support Apercure Surgical Limited at this pivotal stage of its development," said a representative from WNT Ventures. "Apercure’s leadership team, innovative products, and commitment to advancing surgical care are exactly the kind of investment opportunities we look for. We believe in their vision and are excited to help them scale and bring their solutions to market."
The successful funding round is a testament to the growing interest and confidence in Apercure’s mission and its ability to transform the surgical device industry. As Apercure continues to innovate and bring its groundbreaking devices to market, the company is poised to improve surgical outcomes and enhance patient care globally.
With WNT Ventures' backing, Apercure is primed for rapid growth and continued success, paving the way for the next generation of surgical technologies.
17th November 2022
Apercure Surgical Limited Secures Funding from Callaghan Innovation.
Apercure Surgical Limited, a leading innovator in the medical device sector, is proud to announce that it has secured funding from Callaghan Innovation, New Zealand's government agency that supports businesses in their research, development, and innovation efforts. The funding will support Apercure in advancing the development of its next-generation surgical devices, with a focus on enhancing functionality, safety, and patient outcomes.
Callaghan Innovation’s investment in Apercure highlights the agency's commitment to fostering innovation within the medical technology space. The funding will enable Apercure to expand its research and development capabilities, accelerate the prototype testing process, and scale up its manufacturing operations to meet growing market demand. This partnership marks a significant step in Apercure’s mission to create cutting-edge surgical devices that improve the quality of care and outcomes for patients worldwide.
“We are extremely grateful for the support from Callaghan Innovation,” said Gregory Watts, CEO of Apercure Surgical Limited. “This funding provides a unique opportunity for us to fast-track the development of our surgical devices, ensuring we bring the most advanced solutions to market more quickly. Callaghan Innovation’s backing will allow us to continue pushing the boundaries of what’s possible in surgical technology while ensuring our devices meet the highest standards of safety and performance.”
Apercure’s surgical devices are designed with the needs of healthcare professionals and patients in mind. The company is committed to developing innovative products that address current challenges in the medical field, and this funding will support further advancements in its research and clinical trials. Additionally, the funding will be used to strengthen Apercure's regulatory compliance efforts, ensuring that all products meet global standards and are ready for clinical use.
Callaghan Innovation’s investment is a testament to the strength of Apercure’s leadership team and the potential of its innovative surgical devices. The funding will also enable the company to explore new opportunities for international expansion, positioning Apercure for continued success in the global medical device market.
“We are excited to support Apercure Surgical Limited as they advance their cutting-edge technologies,” said a Callaghan Innovation spokesperson. “Apercure’s work aligns with our mission to support New Zealand-based companies that are driving innovation and excellence in the healthcare sector. We look forward to seeing the impact of their work in improving surgical outcomes and patient care.”
The partnership with Callaghan Innovation strengthens Apercure’s position as a leader in the development of surgical devices, providing the resources necessary to bring their groundbreaking products to market. With continued support from Callaghan Innovation and a focus on research and development, Apercure is poised to revolutionize the surgical device industry and improve outcomes for healthcare providers and patients worldwide.
With Callaghan Innovation’s funding, Apercure is set to accelerate the development of its innovative surgical devices, further solidifying its commitment to transforming the future of surgical care.